Clear All
12482 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
31722-0259-28 31722-0259 LENALIDOMIDE LENALIDOMIDE 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral May 11, 2023 In Use
31722-0772-21 31722-0772 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
47781-0488-77 47781-0488 Lenalidomide LENALIDOMIDE 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 3, 2022 In Use
55513-0160-21 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Apr 30, 2026 In Use
00078-0958-19 00078-0958 tisagenlecleucel KYMRIAH 60000000.0 1/1 Immunotherapy CAR-T CD19 Intravenous May 1, 2018 In Use
51144-0003-01 51144-0003 Tisotumab vedotin TIVDAK 40.0 mg/4mL Immunotherapy Drug Antibody Conjugate Tissue factor Intravenous Sep 20, 2021 In Use
00004-0365-09 00004-0365 Peginterferon alfa-2a Pegasys 180.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Nov 1, 2011 In Use
00085-4350-01 00085-4350 Interferon alfa-2b Intron A Immunotherapy Cytokine Interferon Aug 11, 2014 In Use
59651-0347-21 59651-0347 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 6, 2023 In Use
60505-4534-01 60505-4534 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 Mar 8, 2023 In Use
00004-0360-30 00004-0360 Peginterferon alfa-2a Pegasys 135.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Nov 1, 2011 Jan 31, 2019 No Longer Used
72187-0401-01 72187-0401 Tagraxofusp Elzonris 1000.0 ug/mL Immunotherapy Fusion Protein IL3/ CD123 Intravenous Jan 18, 2019 In Use
00007-3260-36 00007-3260 Tositumomab Bexxar Immunotherapy Radioimmunotherapy CD20 Jul 15, 2009 Nov 28, 2014 No Longer Used
60505-4500-02 60505-4500 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 11, 2026 In Use
43598-0516-63 43598-0516 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
60505-4498-02 60505-4498 Pomalidomide Pomalidomide 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 11, 2026 In Use
31722-0770-32 31722-0770 Pomalidomide Pomalidomide 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
45802-0368-62 45802-0368 Imiquimod Imiquimod 12.5 mg/.25g Immunotherapy Immunomodulator Dermatological Agent Topical Nov 9, 2010 In Use
72606-0012-10 72606-0012 Bevacizumab-adcd Vegzelma 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 3, 2023 In Use
70121-1755-01 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 15, 2022 Oct 31, 2028 In Use
31722-0773-01 31722-0773 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
57894-0522-01 57894-0522 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) Rybrevant Faspro 3520.0 mg/22mL, 44000.0 mg/22mL Immunotherapy Monoclonal Antibody EGFR, MET Subcutaneous Feb 13, 2026 In Use
57894-0420-01 57894-0420 Siltuximab Sylvant 100.0 mg/1 Immunotherapy Monoclonal Antibody Interleukin-6 Antagonists Intravenous Apr 23, 2014 Jan 31, 2021 No Longer Used
57894-0514-01 57894-0514 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 2240.0 mg/14mL, 28000.0 mg/14mL Immunotherapy Monoclonal Antibody EGFR, MET Subcutaneous Dec 19, 2025 In Use
31722-0771-01 31722-0771 Pomalidomide Pomalidomide 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use

Found 12482 results — Export these results